Elaine Jones

Elaine Jones is a Board of Director at Kymera Therapeutics. She joined Pfizer Venture Investments as Executive Director, Venture Capital. She is responsible for making and managing venture investments for Pfizer and currently manages the PVI investments in Aquinox Pharmaceuticals (Vancouver, British Columbia), Flexion Therapeutics (Boston, MA), Merus B.V. (Utrecht, The Netherlands), and NeuroTherapeutics Pharma (Chicago, IL). Elaine brings 10 years of venture capital experience and a strong background in research and product assessment, built on her significant experience in pharmaceutical drug discovery and business development to the PVI team. Most recently, Elaine was a General Partner with the venture fund, EuclidSR Partners. There, she was responsible for the fund's investments in Acurian, Fluidigm, InnaPhase and Targacept.Prior to joining ESR, Dr. Jones began her private equity career in 1999 at S.R. One, GlaxoSmithKline's venture fund, where she managed investments including Adolor, Avantium, Nucleonics, Scynexis and Vicuron.Previously, she served as Director of Scientific Licensing for SmithKline Beecham and was a research scientist in SmithKline Beecham Pharmaceutical R&D.Dr. Jones is a graduate of Juniata College and received her Ph.D. in Microbiology from the University of Pittsburgh.